AUG 22, 2013 9:00 AM PDT

Return of Genome Sequencing Results to Physicians and Patients

C.E. Credits: CE
Speaker
  • Director of Social Sciences & Bioethics, Assistant Professor, Scripps Translational Science Institute, Scripps Health & The Scripps Research Institute
    BIOGRAPHY

Abstract
There has been considerable debate in the scientific and clinical communities regarding the return of results from genome sequencing to physicians and patients. Questions surrounding which health care professional(s) should deliver this information, as well as what types of results should be returned loom large. The aim of the Scripps Idiopathic Diseases of huMan (IDIOM) study is to use genome sequencing to inform diagnosis and treatment of idiopathic diseases. As part of this study, we assess patient and provider preferences surrounding the types of results returned from sequencing, as well as perceptions of the return-of-results communication itself. This is done via semi-structured interviews and standardized questionnaires. Data collected to date suggest that the majority of probands and their parents would prefer, if given the choice, to receive sequencing results for the presenting condition, as well as secondary findings in multiple disease categories (e.g., actionable and non-actionable, childhood and adult-onset). Further, data from the completed return-of-results sessions suggest notable variation in patient satisfaction with communication of results by the referring physician. This includes, in some cases, a marked discrepancy between the extent to which the physician felt results were communicated effectively versus the extent to which the patient perceived the communication to be effective. These case-by-case findings will be discussed in detail. Through the Scripps IDIOM study we have begun collection of empirical data on patient preferences and perceptions regarding return of results from genome sequencing for diagnosis and treatment of idiopathic disease. It is our hope that these data will help inform the development of an effective, sustainable, and cost-effective model of return of individual results from genome sequencing in clinical settings.There has been considerable debate in the scientific and clinical communities regarding the return of results from genome sequencing to physicians and patients. Questions surrounding which health care professional(s) should deliver this information, as well as what types of results should be returned loom large. The aim of the Scripps Idiopathic Diseases of huMan (IDIOM) study is to use genome sequencing to inform diagnosis and treatment of idiopathic diseases. As part of this study, we assess patient and provider preferences surrounding the types of results returned from sequencing, as well as perceptions of the return-of-results communication itself. This is done via semi-structured interviews and standardized questionnaires. Data collected to date suggest that the majority of probands and their parents would prefer, if given the choice, to receive sequencing results for the presenting condition, as well as secondary findings in multiple disease categories (e.g., actionable and non-actionable, childhood and adult-onset). Further, data from the completed return-of-results sessions suggest notable variation in patient satisfaction with communication of results by the referring physician. This includes, in some cases, a marked discrepancy between the extent to which the physician felt results were communicated effectively versus the extent to which the patient perceived the communication to be effective. These case-by-case findings will be discussed in detail. Through the Scripps IDIOM study we have begun collection of empirical data on patient preferences and perceptions regarding return of results from genome sequencing for diagnosis and treatment of idiopathic disease. It is our hope that these data will help inform the development of an effective, sustainable, and cost-effective model of return of individual results from genome sequencing in clinical settings.

Show Resources
You May Also Like
MAY 17, 2022 9:00 AM PDT
MAY 17, 2022 9:00 AM PDT
Date: May 17, 2022 Time: 9:00am (PDT), 12:00pm (EDT), 8:00pm (CEST) Gene therapeutics have great potential to treat many severe diseases in an unprecedented, targeted manner. The biopharmace...
JUN 28, 2022 7:00 AM PDT
JUN 28, 2022 7:00 AM PDT
Date: June 07, 2022 Time: 7:00am (PDT), 10:00am (EDT), 4:00pm (CEST) Predictive Genomics (PG) is a powerful capability to help predict disease risk and understand drug responses to improve h...
JUN 28, 2022 7:00 AM PDT
JUN 28, 2022 7:00 AM PDT
Date: June 28, 2022 Time: 3:00pm (BST), 4:00pm (CET), 9:00am (CST), 7am (PST) Light-sheet microscopy is an extremely versatile imaging technique with a vast range of implementations that are...
APR 26, 2022 7:00 AM PDT
C.E. CREDITS
APR 26, 2022 7:00 AM PDT
Date: April 19, 2022 Time: 7:00am (PDT), 10:00am (EDT), 4:00pm (CEST) High-content (HC) phenotypic profiling approaches are a powerful tool to study the effect of biological, genetic, and ch...
MAR 30, 2022 6:00 AM PDT
MAR 30, 2022 6:00 AM PDT
Targeted NGS has been instrumental in helping the healthcare community deliver on the promise of precision medicine. The Ion Torrent Genexus Integrated Sequencer has enabled targeted genomic...
JUN 21, 2022 6:00 AM PDT
JUN 21, 2022 6:00 AM PDT
Date: June 21, 2022 Time: 6:00am (PDT), 9:00am (EDT), 3:00pm (CEST) The global understanding and practice of medicine is currently undergoing a revolutionary change. This shift to precision...
Loading Comments...
Show Resources
Attendees